We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance.
RAJ CREATIONZS / shutterstock.com
AbbVie is advancing its oncology portfolio through two targeted chemo antibody-drug conjugates (ADCs), Elahere and Emrelis, which...
